Seattle Genetics (SGEN.W)
10.41USD
25 Jan 2010
$0.25 (+2.68%)
$10.41
--
$9.76
$9.34
517,624
637,945
$14.94
$7.00
SGEN.W
About
Overall
| Beta: | 1.21 |
| Market Cap (Mil.): | $964.10 |
| Shares Outstanding (Mil.): | 100.53 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| SGEN.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.65 | 3.76 |
| EPS (TTM): | 15.13 | -- | -- |
| ROI: | -- | 1.47 | 2.30 |
| ROE: | -- | 2.41 | 2.82 |
UPDATE 1-Seattle Genetics reports narrower-than-expected Q4 loss
Feb 9 (Reuters) - Biotechnology company Seattle Genetics Inc posted a narrower-than-expected quarterly loss and said it was on track to report top-line results from a pivotal trial of its experimental hodgkin lymphoma drug in the second half of 2010.
Seattle Genetics in licensing deal with Glaxo
(Reuters) - Seattle Genetics Inc said GlaxoSmithKline will pay $12 million upfront for the rights to use its antibody-drug conjugate (ADC) technology, under a collaboration agreement between the two companies.
UPDATE 1-Seattle Genetics in licensing deal with Glaxo
Dec 21 (Reuters) - Seattle Genetics Inc said GlaxoSmithKline will pay $12 million upfront for the rights to use its antibody-drug conjugate (ADC) technology, under a collaboration agreement between the two companies.
Seattle Genetics jumps on Glaxo collaboration
NEW YORK (Reuters) - Seattle Genetics Inc shares jumped 6.3 percent to $9.75 in premarket trade on Monday after the company said it had reached an antibody-drug conjugate collaboration with GlaxoSmithKline .
BEFORE THE BELL-Seattle Genetics jumps on Glaxo collaboration
NEW YORK, Dec 21 (Reuters) - Seattle Genetics Inc shares jumped 6.3 percent to $9.75 in premarket trade on Monday after the company said it had reached an antibody-drug conjugate collaboration with GlaxoSmithKline . [ID:nWNBB3212]
Nikkei likely to gain, but rise limited; eyes on yen
TOKYO, Dec 16 (Reuters) - Japan's Nikkei stock average is likely to rise on Wednesday, with exporters such as Canon Inc getting a boost from a weaker yen, but worry about U.S. inflation prompted by a climb in producer prices may limit gains.
UPDATE 1-Seattle Genetics sells non-U.S. drug rights to Takeda
TOKYO, Dec 15 (Reuters) - Seattle Genetics has sold some rights to a key lymphoma drug to Japan's Takeda Pharmaceutical Co , a vote of confidence for the U.S. biotech firm after it stopped a mid-stage cancer trial this year.
Takeda buys non-U.S. rights to Seattle Genetics drug
TOKYO, Dec 15 (Reuters) - Japan's Takeda Pharmaceutical Co said on Tuesday that it will help develop Seattle Genetics' Hodgkin lymphoma and anaplastic large cell lymphoma drug, brentuximab vedotin (SGN-35).
Biotech fundraising up amid vaccine hype, cash need
PHILADELPHIA/NEW YORK, Oct 7 (Reuters) - Hype about the swine flu vaccines, pent-up demand for cash and a push by major drugmakers to boost their flagging research pipelines has helped lift biotechnology fund-raising 36 percent so far this year.
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 5
(Updates to after the open, adds Caterpillar, Seattle Genetics, Manitowoc, MKS Instruments, Frontier Financial Peregrine, Finisar)
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF56.70 | -0.10 |
| Sanofi-Aventis SA (SASY.PA) | €52.02 | -0.64 |
| Genentech, Inc. (DNA.N) | -- | -- |
| Bayer AG (BAYGn.DE) | €48.22 | +0.38 |
| Bayer AG (BAYE.F) | -- | -- |
| Amgen, Inc. (AMGN.OQ) | $56.83 | -0.38 |
| Bristol Myers Squibb Co. (BMY.N) | $23.89 | -0.36 |
| Bristol Myers Squibb Co. (BMY_p.N) | $439.50 | 0.00 |
| Celgene Corporation (CELG.OQ) | $56.07 | +0.49 |
| Biogen Idec Inc. (BIIB.OQ) | $54.52 | +0.43 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
